Personalis, Inc. Enters Into Research Agreement With Invectys to Provide Comprehensive Tumor Immunogenomics Profiling for Cli...
09 9월 2019 - 9:00PM
Business Wire
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics
for cancer, today announced that it has entered into a research
agreement with Invectys, a biopharmaceutical company focused on the
development of innovative immunotherapy approaches to treat
cancers. Under the terms of the agreement, Personalis will provide
comprehensive tumor immunogenomics capabilities to facilitate
biomarker discovery in chronic lymphocytic leukemia (CLL) patients
enrolled in a Phase II clinical trial assessing the efficacy of
INVAC-1, a DNA plasmid encoding a modified human telomerase reverse
transcriptase (hTERT) protein, as monotherapy or in combination
with ibrutinib.
“Personalis is known for their innovative and expansive cancer
immunogenomics expertise, and we’re delighted to partner with them
on this project to evaluate biomarker signatures in responders and
non-responders to our leading cancer vaccine candidate, INVAC-1,”
said Pierre Langlade Demoyen, CEO of Invectys. “INVAC-1 has the
potential to become a key component of combination therapy
approaches for the treatment of various solid and hematologic
cancer types. Our work with Personalis will help us to determine
which patients are most likely to respond favorably to these novel
treatment regimens.”
Invectys is now enrolling CLL patients in this Phase II,
open-label, single-arm trial consisting of two patient groups: 45
patients receiving INVAC-1 as monotherapy and an additional 45
patients receiving INVAC-1 in combination with ibrutinib, a
Bruton's Tyrosine Kinase inhibitor. The primary goal of the study
is to achieve minimal residual disease negativity in both groups.
The trial is being conducted at the MD Anderson Cancer Center in
Houston, Texas. For more information, please visit
clinicaltrials.gov identifier NCT03265717.
“Invectys has built an exciting pipeline of novel,
next-generation immunotherapies, and we’re thrilled to help drive
their lead program forward,” said John West, CEO of Personalis.
“Having already established ourselves as a leader in comprehensive
tumor immunogenomic profiling and biomarker discovery for solid
tumor indications, we’ve seen increasing use of our capabilities
for biomarker evaluation in hematologic cancer types. This bodes
well as we continue to rollout and onboard customers for our
newly-launched, universal cancer immunogenomics platform, ImmunoID
NeXT™.”
About Personalis, Inc.
Personalis, Inc. is a growing cancer genomics company
transforming the development of next-generation therapies by
providing more comprehensive molecular data about each patient’s
cancer and immune response. The company’s NeXT™ Platform is
designed to adapt to the complex and evolving understanding of
cancer, providing its biopharmaceutical customers with information
on all of the approximately 20,000 human genes, together with the
immune system, from a single tissue sample. The Personalis Clinical
Laboratory is GxP aligned as well as CLIA’88-certified and
CAP-accredited. For more information, please visit
www.personalis.com and follow Personalis on Twitter
(@PersonalisInc).
About Invectys
Founded in 2010 at the Pasteur Institute in Paris, Invectys SA
is a biopharmaceutical company focused on the development of
innovative immuno-oncology treatments. Invectys has raised €38
million. The company has developed a broad pipeline including one
platform designed to provide low-cost, easy-to-administer cancer
therapies, alone or in combination with other treatments such as
immune checkpoint antibodies. Invectys products aim to enlist and
restore natural antitumor efficacy in cancer patients.
Forward-Looking Statements
This press release contains or may imply "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934. For
example, forward-looking statements include statements regarding:
the development as INVAC-1 as a treatment for solid and hematologic
cancer types; and the use and adoption of ImmunoID NeXT™. These
forward-looking statements are subject to risks and uncertainties,
including those discussed in Personalis’ filings with the
Securities and Exchange Commission (SEC), including in the “Risk
Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations” sections of the Company’s most
recently filed periodic reports on Form 10-Q and subsequent filings
and in the documents incorporated by reference therein. Except as
otherwise required by law, Personalis disclaims any intention or
obligation to update or revise any forward-looking statements,
which speak only as of the date hereof, whether as a result of new
information, future events or circumstances or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190909005357/en/
Investor Relations Contact for Personalis: Caroline
Corner investors@personalis.com www.westwicke.com 415-202-5678
Media Contact for Personalis: Jennifer Havlek
pr@personalis.com www.personalis.com 650-752-1300
Media Contact for Invectys: Gilles Petitot
gilles.petitot@acorelis.com www.invectys.com +33-620-276-594
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024